Gunsynd Regulatory News (GUN)

Syntopix Group plc

("Syntopix" or "the Company" or "the Group")

Syntopix announces agreement with Sinclair Pharma

Syntopix Group plc (AIM:SYN), the company focused on topical antimicrobial innovations for products in the medicine and consumer healthcare markets, is pleased to announce that it has signed an agreement with Sinclair Pharma plc (LON:SPH) ("Sinclair"), the international specialty pharma company, to work together on the identification of an antimicrobial compound to synergise and augment the activity of a key product for Sinclair.

Sinclair is a leading skin and mouth disease specialist with sales and marketing operations across Europe and will work in conjunction with Syntopix to develop a product. Should the collaboration result in a product that reaches commercialisation, financial gains from the sales will be shared between the two companies.

Dr Stephen Jones, CEO of Syntopix, says: "We are delighted to be entering into this collaboration with Sinclair. I am very confident that its proprietary compound will be complemented and enhanced by some of the compounds that Syntopix has been identifying in this area over several years. We look forward to sharing exciting compounds and technical expertise with the intention of developing a market leading healthcare product."

- Ends -

For further information, please contact:

Media enquiries:

Notes to editors

About Syntopix Group plc

Syntopix is a specialised research and development business, focusing on topical antimicrobial innovations for products in consumer healthcare and pharmaceutical markets. The Group was founded in 2003 as a spin-out from the University of Leeds by Dr Jon Cove and Dr Anne Eady, two of the world's leading experts in skin microbiology.

The Group's development focus is on its three leading, core compounds SYN0126, SYN1113 and SYN0017. Each has multiple potential uses across a number of large consumer healthcare markets including skincare, hair-care and oral health. Syntopix has developed strong working relationships with a number of major consumer healthcare companies including Proctor & Gamble and is now actively seeking to out-license these products to commercial partners.

Syntopix has a robust pipeline, with a growing library of over 2,500 compounds. Its strategy is to seek to reduce the risks and costs of drug discovery and development by discovering novel uses for known compounds and combinations of compounds, which have established safety profiles.The Group adopts an ongoing filing process that has resulted in 24 core patents/applications.

The Group is based at the Institute of Pharmaceutical Innovation in Bradford, giving access to the expertise in skin biology, formulation and toxicology at the universities of Bradford and Leeds.

Syntopix' shareholders include Techtran Group Limited (a subsidiary of IP Group plc), The Wellcome Trust Limited, The University of Leeds and Ridings Early Growth Investment Company Limited. Syntopix joined the AIM market of the London Stock Exchange in March 2006. For more information, please visit our website at www.syntopix.com.